Evofem and Aditxt amend merger, extend third equity investment deadline contingent on Aditxt raising $20M

Evofem Biosciences, Inc.

Third Parent Equity Investment deadline moved to earlier of Sep 6, 2024 or 5 business days after Aditxt closes a ≥$20M public offering.
Aditxt must purchase 2,000 shares of Evofem Series F-1 Preferred for $2,000,000 on that date.
Other investment dates unchanged: $500k (Jul 12), $500k (Aug 9), $1,000k (Sep 30).
Amendment signed Aug 16, 2024 by CEOs of Evofem (Saundra Pelletier) and Aditxt (Amro Albanna).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.